Evidence map›Paper›PMID 38516167›Full record

ReviewRSC advances2024

Recent advancements in the specific determination of carcinoembryonic antigens using MOF-based immunosensors.

Zahra Karimzadeh, Mansour Mahmoudpour, Elaheh Rahimpour, Abolghasem Jouyban

Open access · goldAbstract readReview
In one paragraph

Review in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Zahra KarimzadehPharmaceutical Analysis Research Center, Faculty of Pharmacy, Tabriz University of Medical Sciences Tabriz Iran.
Mansour MahmoudpourMiandoab Schools of Medical Sciences Miandoab Iran.
Elaheh RahimpourPharmaceutical Analysis Research Center, Faculty of Pharmacy, Tabriz University of Medical Sciences Tabriz Iran.ORCID https://orcid.org/0000-0002-4037-9436
Abolghasem JouybanPharmaceutical Analysis Research Center, Faculty of Pharmacy, Tabriz University of Medical Sciences Tabriz Iran.ORCID https://orcid.org/0000-0002-4670-2783
Tabriz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carcinoembryonic antigens (CEAs) are prominent cancer biomarkers that enable the early detection of numerous cancers. For effective CEA screening, rapid, portable, efficient, and sensitive diagnosis approaches should be devised. Metal-organic frameworks (MOFs) are porous crystalline materials that have received major attention for application in high-efficiency signal probes owing to their advantages such as large specific surface area, superior chemical stability and tunability, high porosity, easy surface functional modification, and adjustable size and morphology. Immunoassay strategies using antigen-antibody specific interaction are one of the imperative means for rapid and accurate measurement of target molecules in biochemical fields. The emerging MOFs and their nanocomposites are synthesized with excellent features, providing promising potential for immunoassays. This article outlines the recent breakthroughs in the synthesis approaches of MOFs and overall functionalization mechanisms of MOFs with antigen/antibody and their uses in the CEA immunoassays, which operate according to electrochemical, electrochemiluminescent and colorimetric techniques. The prospects and limitations of the preparation and immunoassay applications of MOF-derived hybrid nanocomposites are also discussed at the end.

Identifiers

PMID38516167
PMCPMC10955552
OpenAlexW4393045235

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.